BARCELONA, Spain | Aug 01, 2006 | The Business Intelligence firm La Merie S.L. reported today that the huge market of US$ 7.6 bln in 2005 and the clinical validation of the target in many inflammatory indications has filled the pipeline of follow-on TNF-antagonists. Sales of the three marketed TNF antagonists etanercept, infliximab and adalimumab grew by 42, 18 and 64 %, respectively, in 2005 and are expected to further grow due to the still expanding number of approved clinical indications of inflammatory diseases including rheumatoid arthritis and inflammatory bowel diseases. At least six follow-on TNF antagonists are in clinical development and more than 16 projects in preclinical stages. Apart from antibody-based constructs, other technologies such as small molecules, vaccines, proteins, gene therapy, RNAi make use of the validated target in an attractive market to validate their technology at low development risk. These results and more were found in a competitor analysis conducted by La Merie Business Intelligence. The findings of the search can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.
The range of indications for which at least one of the three branded TNF antagonists obtained approval ranges from rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (CD), pediatric CD, ulcerative colitis and psoriasis. Further inflammatory indications such as asthma are under evaluation. The most advanced clinical stage follow-on TNF-antagonist are human or humanized/optimized antibodies in order to reduce the immunogenicity risk seen with chimeric molecules. Small molecules as selective or dual TNF antagonists also have reached clinical evaluation.
The preclinical pipeline of TNF antagonists consists of molecules derived from new technologies or molecules exploring other strategies such as vaccination or oral delivery. Engineered proteins and antibodies make up most of the pipeline attempting to develop and validate the respective technology by using a validated target in an attractive market.
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on R&D in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. For more information visit www.pipelinereview.com,.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
SOURCE: La Merie Business Intelligence
Message posted by: Jorge Márquez
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...